N-Terminally PEGylated Human Interferon-β-1a with Improved Pharmacokinetic Properties and in Vivo Efficacy in a Melanoma Angiogenesis Model
The DOI matches its Crossref record.
Abstract
PEGylation of IFN-alpha has been used successfully to improve the pharmacokinetic properties and efficacy of the drug. To prepare a PEGylated form of human interferon-beta-1a (IFN-beta-1a) suitable for testing in vivo, we have synthesized 20 kDa mPEG-O-2-methylpropionaldehyde and used it to modify the N-terminal alpha-amino group of the cytokine. The PEGylated protein retained approximately 50% of the activity of the unmodified protein and had significantly improved pharmacokinetic properties following intravenous administration in rats. The clearance and volume of distribution at steady state were reduced approximately 30-fold and approximately 4-fold, respectively, resulting in a significant increase in systemic exposure as determined by the area under the curve. The elimination half-life of the PEGylated protein was approximately 13-fold greater than for the unmodified protein. The unmodified and PEGylated proteins were tested for their ability to inhibit the formation of radially oriented blood vessels entering the periphery of human SK-MEL-1 melanoma tumors in athymic nude homozygous (nu/nu) mice. In a single dose comparison study, administration of 1 x 10(6) units of unmodified IFN-beta-1a resulted in a 29% reduction in vessel number, while 1 x 10(6) units of PEGylated IFN-beta-1a resulted in a 58% reduction. Both treatments resulted in statistically significant reductions in mean vessel number as compared to the vehicle (control)-treated mice, with the PEGylated IFN-beta-1a-treated mice showing a statistically significantly greater reduction in mean vessel number as compared to the unmodified IFN-beta-1a-treated mice. In a multiple versus single dose comparison study, daily administration of 1 x 10(6) units of unmodified IFN-beta-1a for 9 days resulted in a 51% reduction in vessel number, while a single dose of 1 x 10(6) units of the PEGylated protein resulted in a 66% reduction. Both treatments resulted in statistically significant reductions in mean vessel number as compared to the vehicle-treated mice, with the PEGylated IFN-beta-1a-treated mice showing a statistically significantly greater reduction in mean vessel number as compared to the unmodified IFN-beta-1a-treated mice. Therefore, the improved pharmacokinetic properties of the modified protein translated into improved efficacy. Since unmodified IFN-beta is used for the treatment of multiple sclerosis and hepatitis C virus infection, a PEGylated form of the protein such as 20 kDa mPEG-O-2-methylpropionaldehyde-modified IFN-beta-1a may serve as a useful adjunct for the treatment of these diseases. In addition, the antiangiogenic effects of PEGylated IFN-beta-1a may be harnessed for the treatment of certain cancers, either as a sole agent or in combination with other antitumor drugs.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cited by
Herzberger, J., Niederer, K., Pohlit, H., Seiwert, J., Worm, M., Wurm, F. R., & Frey, H. (2016) · Chemical Reviews · doi:10.1021/acs.chemrev.5b00441 · Cited by 865
Turecek, P. L., Bossard, M. J., Schoetens, F., & Ivens, I. A. (2016) · Journal of Pharmaceutical Sciences · doi:10.1016/j.xphs.2015.11.015 · Cited by 733
PEGylation of therapeutic proteins
Jevševar, S., Kunstelj, M., & Porekar, V. G. (2010) · Biotechnology Journal · doi:10.1002/biot.200900218 · Cited by 681
Hoang Thi, T. T., Pilkington, E. H., Nguyen, D. H., Lee, J. S., Park, K. D., & Truong, N. P. (2020) · Polymers · doi:10.3390/polym12020298 · Cited by 668
“PEGylation has been shown to improve the in vivo stability of micelles, liposomes, dendrimers, gold nanoshells, quantum dots and polymeric NPs, thus providing more effective therapeutic action [7,25].”
BackgroundChoosing an effective protein bioconjugation strategy
Stephanopoulos, N., & Francis, M. B. (2011) · Nature Chemical Biology · doi:10.1038/nchembio.720 · Cited by 634
Koniev, O., & Wagner, A. (2015) · Chem. Soc. Rev. · doi:10.1039/c5cs00048c · Cited by 594
The Pharmacology of PEGylation: Balancing PD with PK to Generate Novel Therapeutics
Fishburn, C. S. (2008) · Journal of Pharmaceutical Sciences · doi:10.1002/jps.21278 · Cited by 474
Calabresi, P. A., Kieseier, B. C., Arnold, D. L., Balcer, L. J., Boyko, A., Pelletier, J., Liu, S., Zhu, Y., Seddighzadeh, A., Hung, S., et al. (2014) · The Lancet Neurology · doi:10.1016/s1474-4422(14)70068-7 · Cited by 398
Targeting the N terminus for site-selective protein modification
Rosen, C. B., & Francis, M. B. (2017) · Nature Chemical Biology · doi:10.1038/nchembio.2416 · Cited by 389
N‐Terminal Protein Modification through a Biomimetic Transamination Reaction
Gilmore, J. M., Scheck, R. A., Esser‐Kahn, A. P., Joshi, N. S., & Francis, M. B. (2006) · Angewandte Chemie International Edition · doi:10.1002/anie.200600368 · Cited by 381
Houde, D., Berkowitz, S. A., & Engen, J. R. (2011) · Journal of Pharmaceutical Sciences · doi:10.1002/jps.22432 · Cited by 375
One-step site-specific modification of native proteins with 2-pyridinecarboxyaldehydes
MacDonald, J. I., Munch, H. K., Moore, T., & Francis, M. B. (2015) · Nature Chemical Biology · doi:10.1038/nchembio.1792 · Cited by 317
Polypeptide–polymer bioconjugates
Canalle, L. A., Löwik, D. W. P. M., & van Hest, J. C. M. (2010) · Chem. Soc. Rev. · doi:10.1039/b807871h · Cited by 265
Stability of responsive polymer–protein bioconjugates
Shakya, A. K., Sami, H., Srivastava, A., & Kumar, A. (2010) · Progress in Polymer Science · doi:10.1016/j.progpolymsci.2010.01.003 · Cited by 110
Muneeruddin, K., Bobst, C. E., Frenkel, R., Houde, D., Turyan, I., Sosic, Z., & Kaltashov, I. A. (2017) · The Analyst · doi:10.1039/c6an02041k · Cited by 38
Metadata
- Authors
- Baker, D. P., Lin, E. Y., Lin, K., Pellegrini, M., Petter, R. C., Chen, L. L., Arduini, R. M., Brickelmaier, M., Wen, D., Hess, D. M., Chen, L., Grant, D., Whitty, A., Gill, A., Lindner, D. J., & Pepinsky, R. B.
- Venue
- Bioconjugate Chemistry
- Publisher
- American Chemical Society (ACS)
- Published
- 2005-12-03
- Volume
- 17
- Issue
- 1
- Pages
- 179-188
- ISSN
- 1043-1802 (ISSN-L)
- 1520-4812
- OpenAlex
- W2039871617
- Cited by
- 144
- References
- 0
- FWCI
- 1.97
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.